TNL Mediagene Receives Nasdaq Deficiency Letter Over $918k Equity Shortfall
TNL Mediagene reported stockholders’ equity of $918,088 for year-end 2025, falling short of Nasdaq’s $2.5 million minimum requirement, prompting a deficiency letter. The company must submit a compliance plan by June 22, 2026 and could receive up to 180 days to restore equity and retain its Nasdaq listing.
1. Nasdaq Deficiency Letter Details
TNL Mediagene received a Nasdaq Listing Qualifications notice dated May 6, 2026, citing non-compliance with Listing Rule 5550(b)(1) after reporting just $918,088 in stockholders’ equity versus the $2.5 million minimum. The notice does not trigger immediate delisting but initiates a 45-day deadline to propose corrective actions.
2. Compliance Plan and Next Steps
Management is evaluating options such as equity financing, asset sales or debt conversion to regain compliance. If Nasdaq accepts the submitted plan by June 22, 2026, TNL Mediagene may be granted up to 180 calendar days to evidence restored equity and maintain its Nasdaq Capital Market listing.